RNAi -- functions specifically to silence, or deactivate, genes. Among other applications, it promises to be groundbreaking ...

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...

Fintel reports that on March 24, 2025, JP Morgan upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

The aggregate gross proceeds to Benitec from the underwritten offering and the concurrent registered direct offering are expected to be approximately $30 million, prior to deducting underwriting ...

A simple, freely available analysis tool and hardware for analyzing fruit flies allows opportunities for researchers in ...

Silexion Therapeutics completes development plan for next-generation siRNA candidate SIL204; plans to present at 2025 NeauxCancer Conference: Grand Cayman, Cayman Islands Tuesday, ...

This milestone would mark a significant turning point for Alnylam, which has invested heavily in research and development to build its RNAi platform and pipeline. The cornerstone of Alnylam’s ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...